MediWound Announces Phase III CIDS Publication on NexoBrid® for Pediatric Burn Care

Core Insights - The publication of the Phase III Children Innovative Debridement Study (CIDS) confirms NexoBrid's superiority over standard of care in treating pediatric patients with deep thermal burns [1][2][4] Group 1: Study Findings - NexoBrid achieved complete eschar removal in a median time of one day compared to six days with standard of care (p < 0.001) [7] - The mean percentage of wound area surgically excised was significantly lower in the NexoBrid arm (1.5%) compared to standard of care (48.1%) (p < 0.001) [7] - Only 8.3% of patients treated with NexoBrid required surgical excision, while 64.4% of those treated with standard of care did [7] - At 12 months, NexoBrid demonstrated comparable cosmesis and functional outcomes to standard of care, with lower MVSS scores of 3.8 in the NexoBrid arm versus 4.9 in the standard of care (p < 0.001) [5] Group 2: Clinical Significance - NexoBrid is recognized as a rapid, effective, and non-surgical alternative for eschar removal in pediatric burn patients, addressing the unique challenges of treating this demographic [2][3] - The study involved 145 pediatric patients across 36 burn centers in the US, EU, Israel, and India, highlighting its multinational scope [4] Group 3: Company Overview - MediWound Ltd. is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair, with NexoBrid being its first FDA- and EMA-approved orphan biologic for eschar removal [9][10] - The company is advancing EscharEx®, a promising candidate currently in Phase III development for chronic wound debridement, which presents a unique opportunity for significant market growth [10]